Minimal Residual Disease in Melanoma

I Biology of Micrometastases and Advances in Methods for Detection.- The Biology of Melanoma Micrometastases.- Disseminated Tumor Cells: Diagnosis, Prognostic Relevance, and Phenotyping.- Nested Quantitative Real Time PCR for Detection of Occult Tumor Cells.- Detection of Micrometastasis Through Tissue-Specific Gene Expression: Its Promise and Problems.- Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients.- Rapid Enrichment and Detection of Melanoma Cells from PBMC by a New Assay Combining Immunomagnetic Cell Sorting and Immunocytochemical Staining.- II. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow.- Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Detection of Melanoma-Related Transcripts in the Peripheral Blood and Bone Marrow of Patients with Malignant Melanoma. What Have We Learned?.- The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma.- Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients.- Facts and Pitfalls in the Detection of Tyrosinase mRNA in the Blood of Melanoma Patients by RT-PCR.- Morphologically Intact Melanoma Cells May Be Detected in Peripheral Blood of Melanoma Patients.- Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase mRNA in Bone Marrow and Survival Time.- III. Detection of Minimal Residual Disease in Sentinel Nodes.- The Predictive Value of the Sentinel Lymph Node in Malignant Melanomas.- Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma.- IV. Early Recognition and Monitoring by Serological Markers.- Monitoring Malignant Melanoma with the S-100B Tumour Marker.- Melanoma Inhibitory Activity (MIA), a Serological Marker of Malignant Melanoma.- Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients.- V. Clinical Relevance of Micrometastases Detection.- Molecular